Loading
Life sciences · Journal article
Frontiers in Microbiology · September 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Depression is a major global public health challenge with limitations in current therapies. Emerging evidence highlights that gut microbiota (GM) critically regulates the gut-brain axis via tryptophan (Trp) metabolism. Trp is metabolized through host-directed serotonin (5-HT) and kynurenine (KYN) pathways, as well as microbiota-specific indole derivative pathways. In depression, gut dysbiosis shifts Trp metabolism toward the KYN pathway, leading to accumulation of neurotoxic metabolites such as quinolinic acid and reduced 5-HT synthesis. Microbiota-derived indoles, functioning as key aryl hydrocarbon receptor (AhR) ligands, regulate blood-brain barrier integrity, neuroinflammation, and hypothalamic-pituitary-adrenal (HPA) axis function through AhR activation, thereby exerting neuroprotective or pro-inflammatory effects depending on the specific ligand and context. Interventions targeting the Trp-microbiota axis include dietary modifications, probiotics, antibiotics, traditional Chinese medicine, fecal microbiota transplantation, and metabolite supplementation. However, clinical translation is hindered by population heterogeneity, strain specificity, and insufficient dynamic monitoring. Future research should integrate multi-omics and neuroimaging approaches to improve patient stratification and advance Trp metabolism-based precision psychiatry, while emerging computational tools may further support biomarker integration and treatment prediction.